HER2-positive breast cancer trial after incomplete neoadjuvant therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 study tests giving trastuzumab and pertuzumab as additional (adjuvant) treatment after you had those same medicines before surgery but still had remaining cancer. It may help lower the chance that HER2-positive breast cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be female, age 18 to 75
- Have an ECOG performance status of 0 to 1 (you’re able to do most normal activities)
- Have invasive HER2-positive breast cancer confirmed by pathology (HER2 “3+” on the IHC test and HER2 gene amplification/strong signal on the lab test)
- You had neoadjuvant trastuzumab + pertuzumab, had surgery, and pathology showed leftover invasive cancer in the breast or underarm lymph nodes (not a complete response)
- You finished trastuzumab + pertuzumab after surgery and the last trastuzumab dose ended within the past 1 year; you must have received at least 24 weeks (8 cycles) total during neoadjuvant and/or adjuvant treatment
- Your blood counts and organ tests are within required limits (for example, enough white blood cells, platelets, hemoglobin, and acceptable liver function) and you can manage contraception for 8 weeks after the last dose if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This Phase 2 trial studies a second anti-HER2 treatment (given after surgery) to help lower the risk of breast cancer coming back in people with very small, node-negative, HER2-positive tumors. It will also closely monitor heart function and other side effects because these medicines can affect the body.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.